Cargando…

Phospho-PRAS40(Thr246) predicts trastuzumab response in patients with HER2-positive metastatic breast cancer

Resistance to trastuzumab is frequently observed during the treatment of patients with human epidermal growth factor 2 (HER2)-positive metastatic breast cancers. The aim of the present study was to determine if the phosphorylated proline-rich Akt substrate of 40 kDa (phospho-PRAS40(Thr246)), a novel...

Descripción completa

Detalles Bibliográficos
Autores principales:	YUAN, KAI, WU, HONGYAN, WANG, YULONG, CHEN, HONGQIANG, JIAO, MINGWEN, FU, RONGZHAN
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2015
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301480/ https://www.ncbi.nlm.nih.gov/pubmed/25621052 http://dx.doi.org/10.3892/ol.2014.2744

Ejemplares similares

Prognostic role of phospho-PRAS40 (Thr246) expression in gastric cancer
por: Lu, Yi-Zhuo, et al.
Publicado: (2013)

Effect of PI3K/Akt Signaling Pathway on PRAS40Thr246 Phosphorylation in Gastric Cancer Cells
por: LU, Yizhuo, et al.
Publicado: (2019)

PRAS40 signaling in tumor
por: Lv, Dan, et al.
Publicado: (2017)

Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality
por: Shipitsin, Michail, et al.
Publicado: (2014)

PRAS40 hyperexpression promotes hepatocarcinogenesis
por: Qi, Zhaolai, et al.
Publicado: (2020)

Improved false negative rate of axillary status using sentinel lymph node biopsy and ultrasound-suspicious lymph node sampling in patients with early breast cancer
por: Wang, Yulong, et al.
Publicado: (2015)

mTOR/PRAS40 interaction: Hypertrophy or proliferation
por: Völkers, Mirko, et al.
Publicado: (2013)

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
por: Cheng, Huan, et al.
Publicado: (2014)

Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer
por: Callahan, Rena
Publicado: (2014)

Trastuzumab beyond progression in HER2‐positive metastatic breast cancer
por: Al‐Naqqash, Manwar, et al.
Publicado: (2021)

PRAS40 Is an Integral Regulatory Component of Erythropoietin mTOR Signaling and Cytoprotection
por: Chong, Zhao Zhong, et al.
Publicado: (2012)

Structural Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40
por: Yang, Haijuan, et al.
Publicado: (2017)

Bloom Syndrome Protein Activates AKT and PRAS40 in Prostate Cancer Cells
por: Chen, Kun, et al.
Publicado: (2019)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
por: Dogan, Izzet, et al.
Publicado: (2023)

Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations
por: Jeyakumar, Alwin, et al.
Publicado: (2012)

Maintenance Therapy with Trastuzumab in Her2 Positive Metastatic Parotid Ductal Adenocarcinoma
por: Iqbal, Muhammad Shahid, et al.
Publicado: (2014)

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
por: de Oliveira Taveira, Mateus, et al.
Publicado: (2017)

PRAS40 prevents development of diabetic cardiomyopathy and improves hepatic insulin sensitivity in obesity
por: Völkers, Mirko, et al.
Publicado: (2014)

TIFA promotes colorectal cancer cell proliferation in an RSK‐ and PRAS40‐dependent manner
por: Shen, Wenzhi, et al.
Publicado: (2022)

Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
por: Tsang, R Y, et al.
Publicado: (2012)

Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
por: Sawaki, Masataka
Publicado: (2014)

PRAS40 and PRR5-Like Protein Are New mTOR Interactors that Regulate Apoptosis
por: Thedieck, Kathrin, et al.
Publicado: (2007)

PRAS40 promotes NF-κB transcriptional activity through association with p65
por: Zhu, G, et al.
Publicado: (2017)

Corrigendum to ‘PRAS40 hyperexpression promotes hepatocarcinogenesis’ [EBioMedicine 51 (2020) 102,604]
por: Qi, Zhaolai, et al.
Publicado: (2020)

CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer
por: Sun, Weilin, et al.
Publicado: (2022)

Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
por: Orlando, Laura, et al.
Publicado: (2006)

Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
por: Antonarelli, G., et al.
Publicado: (2023)

Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin(®)) in patients with HER2-positive metastatic breast cancer
por: Chen, Xiaoying, et al.
Publicado: (2019)

The Molecular Landscape and Biological Alterations Induced by PRAS40-Knockout in Head and Neck Squamous Cell Carcinoma
por: Chen, Gang, et al.
Publicado: (2021)

Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin(®)) in patients with HER2‑positive metastatic breast cancer
por: Chen, Xiaoying, et al.
Publicado: (2019)

Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis
por: Han, Yiqun, et al.
Publicado: (2019)

PB.40. What happens to the ductal carcinoma in situ in HER2-positive cancers treated with neoadjuvant chemotherapy and trastuzumab?
por: Millican-Slater, R, et al.
Publicado: (2014)

Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature
por: Firwana, Belal, et al.
Publicado: (2012)

Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
por: Yu, Anthony F., et al.
Publicado: (2016)

Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
por: Al Rabadi, Luai S., et al.
Publicado: (2021)

Phase I/II Trial of Ruxolitinib in Combination with Trastuzumab in Metastatic HER2 Positive Breast Cancer
por: Kearney, Matthew, et al.
Publicado: (2021)

Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
por: Nakajima, Hiromichi, et al.
Publicado: (2022)

Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy
por: Zhang, Yanqiang, et al.
Publicado: (2022)

Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018
por: Kaplan, Henry G., et al.
Publicado: (2022)

Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
por: Waks, Adrienne G, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v13voel5iab4en76fem5r1l28o